SynthesisFrontiers in oncology2026
LncRNA DLEU1 as a novel therapeutic target and prognostic biomarker in various malignancies: a meta-analysis, bioinformatics analysis and systematic review.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Accumulating evidence indicates that the aberrantly expressed long non-coding RNA DLEU1 may serve as a potential therapeutic target and prognostic biomarker in various cancers; however, these findings remain inconclusive. This study systematically evaluated the prognostic value of DLEU1 via a meta-analysis, while also summarizing its biological functions and underlying mechanisms in malignancies. Methods: A systematic literature search was performed in PubMed, Web of Science, Embase, and the Cochrane Library from inception until October 10, 2025. Pooled hazard ratios or odds ratios with 95% confidence intervals were calculated to assess the associations between DLEU1 expression and patient survival or clinicopathological parameters. These findings were subsequently validated using the GEPIA2 platform. Potential target genes of DLEU1 were predicted via the StarBase database, followed by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses. Additionally, we systematically reviewed and summarized the reported functional roles and molecular mechanisms of DLEU1 over the past five years. Results: This meta-analysis, incorporating nine studies with a total of 938 cancer patients, demonstrated that elevated DLEU1 expression was significantly associated with shortened overall survival and adverse clinicopathological features, including lymph node metastasis and advanced TNM stage. In contrast, no significant correlations were observed with age, gender, tumor size, or tumor differentiation. Independent validation via the GEPIA2 database confirmed DLEU1 upregulation in six cancer types and its correlation with poorer survival. Furthermore, a total of 254 potential target genes of DLEU1 were identified through StarBase, and these target genes were significantly enriched in various cancer-related pathways, such as Rap1 signaling pathway, cAMP signaling pathway, PI3K-Akt signaling pathway, apoptosis, and calcium signaling pathway. Conclusion: Upregulated expression of lncRNA DLEU1 is associated with adverse clinicopathological features and poor prognosis in cancer patients, establishing it as a promising prognostic biomarker and therapeutic target across multiple malignancies. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251167807.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.